[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alpha Tau Medical Ltd Cl A (DRTS)

Alpha Tau Medical Ltd Cl A (DRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,347,664
  • Shares Outstanding, K 90,326
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,630 K
  • EBIT $ -13 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 29.44

Options Overview Details

View History
  • Implied Volatility 74.93% (+7.72%)
  • Historical Volatility 64.55%
  • IV Percentile 3%
  • IV Rank 1.04%
  • IV High 812.34% on 12/09/25
  • IV Low 67.21% on 08/21/26
  • Expected Move (DTE 25) 0.85 (5.78%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,296
  • Volume Avg (30-Day) 615
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 17,788
  • Open Int (30-Day) 21,967
  • Expected Range 13.85 to 15.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 2
  • High Estimate $-0.13
  • Low Estimate $-0.15
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.96 +34.12%
on 07/29/26
15.02 -2.13%
on 08/21/26
+2.20 (+17.60%)
since 07/24/26
3-Month
8.75 +68.00%
on 06/09/26
15.02 -2.13%
on 08/21/26
+4.66 (+46.41%)
since 05/22/26
52-Week
3.09 +375.73%
on 08/25/25
15.02 -2.13%
on 08/21/26
+11.54 (+365.19%)
since 08/22/25

Most Recent Stories

More News
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee

WALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano,” or the “Company”) today announced the appointment of Nadav Kidron to its Board...

ORMP : 4.82 (+0.21%)
LFWD : 7.29 (-0.41%)
NNDM : 1.5400 (unch)
DRTS : 14.70 (-1.47%)
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial...

DRTS : 14.70 (-1.47%)
DRTSW : 4.00 (-5.66%)
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha...

DRTS : 14.70 (-1.47%)
DRTSW : 4.00 (-5.66%)
Alpha Tau Medical's Glioblastoma Data Could Redefine How the Street Values This Earnings Call

Barchart Research What to Expect from DRTS Earnings DRTS Generated August 7, 2026 Current Price $13.14 EPS Estimate $$-0.14 Consensus Rating Moderate Buy Average Move 5.09% Alpha Tau Medical's Glioblastoma...

DRTS : 14.70 (-1.47%)
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's...

- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT ® in combination with pembrolizumab...

DRTS : 14.70 (-1.47%)
DRTSW : 4.00 (-5.66%)
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the...

DRTS : 14.70 (-1.47%)
DRTSW : 4.00 (-5.66%)
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world’s...

DRTS : 14.70 (-1.47%)
DRTSW : 4.00 (-5.66%)
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven...

DRTS : 14.70 (-1.47%)
DRTSW : 4.00 (-5.66%)
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S. uro-oncology landscape  - Collaboration...

DRTS : 14.70 (-1.47%)
DRTSW : 4.00 (-5.66%)
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of...

DRTS : 14.70 (-1.47%)
DRTSW : 4.00 (-5.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alpha Tau Medical Ltd. is a medical device company. It focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha Tau Medical Ltd., formerly known as Healthcare Capital Corp., is based in JERUSALEM.

See More

Key Turning Points

3rd Resistance Point 15.37
2nd Resistance Point 15.19
1st Resistance Point 14.94
Last Price 14.70
1st Support Level 14.51
2nd Support Level 14.33
3rd Support Level 14.08

See More

52-Week High 15.02
Last Price 14.70
Fibonacci 61.8% 10.46
Fibonacci 50% 9.06
Fibonacci 38.2% 7.65
52-Week Low 3.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.